Pay in 4 interest-free payments of $23.75 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors
also known as PF-04449913
There is no formal name yet
Schalekamp MA et al
In order to examine the role of PKC in p38MAPK phosphorylation
A-867744 - CAS# 1000279-69-5 terin) Phase I dose-escalation study ofA 867744 is a type II PAM with good potency and selectivity. A 867744 showed acceptable pharmacokinetic profile across species and brain levels sufficient to modulate alpha7 nAChRs. In a rodent model of sensory gating, A 867744 normalized gating deficits. A 867744 represents a novel class of molecules capable of allosteric modulation of the alpha7 nAChRs. A 867744 potentiated acetylcholine (ACh) evoked currents, with an EC(50) value of approximately 1
US$ 40.00
US$ 120.00
US$ 48.00
US$ 42.00
US$ 50.00
US$ 160.00
US$ 55.00
US$ 36.00
US$ 60.00
US$ 75.00
US$ 58.00
US$ 44.00
US$ 180.00
US$ 50.00
US$ 36.00